I read a letter to the editor in the Ocular Surgery News from a doctor who was very frustrated with the studies that each drug rep shows him that proves one glaucoma medication for controlling ocular hypertension is better than the other. He suggested, and I agree, that this essentially “proves” that corporate-sponsored studies are biased, for how could experts studying the same thing consistently come to different conclusions, each one coincidentally proving that the product made by their sponsor is the best?

So, I have come to the point where I tell my reps that when I choose a prostaglandin, I simply toss a coin. This way, the reps don’t harrass me! Or, I choose based on the patient’s insurance coverage. I wonder if anyone out there really sees a significant difference among the three in terms of efficacy ( we all know that Xalatan has the least redness).